Anima Biotech signs $1.05bn discovery and development deal with Lilly

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/HeitiPaves)
(Image: Getty/HeitiPaves)

Related tags: Drug discovery, Lilly, Technology, Big data

Anima Biotech is eligible to receive up to $1.05bn as part of a multi-year drug discovery and development agreement with Lilly.

Under the exclusive agreement with Eli Lilly and Company, Anima Biotech will use its technology platform for the discovery and development of translation inhibitors for several undisclosed target proteins.

According to the company, Anima’s Translation Control Platform is “strategically structured for collaborations with multiple pharma partners.”​ The technology combines “new biology with proprietary image analysis and high-performance big data software,”​ and is protected by five patents.

Lilly will be responsible for clinical development and any potential product commercialization.

Anima will receive $30m in upfront payments and $14m in research funding and is eligible to receive up to $1.05bn if it achieves all future development and commercial milestones.

Additionally, Anima is entitled to low- to mid-single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

Anima Biotech has not responded to a request for comment.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Related suppliers

Follow us


View more